AI Article Synopsis
- The study focused on the effectiveness of tigecycline against ESBL-producing Enterobacteriaceae and MRSA, which are significant hospital-associated infections.
- More than 94% of the tested bacterial isolates were found to be susceptible to tigecycline.
- The minimum inhibitory concentration (MIC) values indicated that tigecycline works well, especially at low concentrations (0.25 to 2 mg/L for ESBL bacteria and 0.125 mg/L for MRSA).
Article Abstract
Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and methicillin resistant Staphylococcus aureus (MRSA) are important nosocomial pathogens. This study reports the in vitro activity of tigecycline against 573 and 482 ESBL-producing Enterobacteriaceae and MRSA isolates, respectively. More than 94% of all tested isolates were susceptible to tigecycline; MIC(90) found was 0.25 to 2 mg/L for ESBL-producing Enterobacteriaceae and was 0.125 mg/L for MRSA. Tigecycline demonstrated excellent in vitro activity against a wide spectrum of nosocomial pathogens.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.diagmicrobio.2010.12.018 | DOI Listing |
Publication Analysis
Top Keywords
vitro activity
12
esbl-producing enterobacteriaceae
12
activity tigecycline
8
enterobacteriaceae mrsa
8
nosocomial pathogens
8
tigecycline
4
tigecycline extended-spectrum
4
extended-spectrum β-lactamase-producing
4
enterobacteriaceae
4
β-lactamase-producing enterobacteriaceae
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!